Patents by Inventor Simon Diep

Simon Diep has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms
    Publication number: 20230218559
    Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutarate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.
    Type: Application
    Filed: September 27, 2022
    Publication date: July 13, 2023
    Inventors: Jing Huang, Randall M. Chin, Simon Diep, Melody Y. Pai, Brett Eugene Lomenick, Xudong Fu, Karen Lynn Reue, Laurent Vergnes, Michael E. Jung, Gang Deng, Heejun Hwang, Meisheng Jiang
  • Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms
    Publication number: 20190192470
    Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutarate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.
    Type: Application
    Filed: March 9, 2019
    Publication date: June 27, 2019
    Inventors: Jing Huang, Randall M. Chin, Simon Diep, Melody Y. Pai, Brett Eugene Lomenick, Xudong Fu, Karen Reue, Laurent Vergnes, Michael E. Jung, Gang Deng, Heejun Hwang, Meisheng Jiang
  • Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms
    Publication number: 20160354334
    Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutamate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.
    Type: Application
    Filed: February 11, 2015
    Publication date: December 8, 2016
    Inventors: Jing Huang, Randall Chin, Simon Diep, Melody Y. Pai, Brett E. Lomenick, Xudong Fu, Karen Reue, Laurent Vergnes, Michael E. Jung, Gang Deng, Heejun Hwang, Meisheng Jiang
  • Use of Pateamine A for the treatment of age-related muscle wasting
    Patent number: 9358249
    Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: June 7, 2016
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep
  • TRANSLATION FACTORS AS ANTI-AGING DRUG TARGETS
    Publication number: 20110288153
    Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.
    Type: Application
    Filed: November 18, 2009
    Publication date: November 24, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jing Huang, Rui Hao, Brett Eugene Lomenick, Nao Jonai, Simon Diep